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Background: Progesterone supplementation after in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI)
can improve the rates of clinical pregnancy and live birth, but the optimal duration of treatment remains
controversial. The objective of this meta-analysis was to investigate the effects of early progesterone cessation on
pregnancy outcomes in women undergoing IVF/ICSI.
Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the
Chinese biomedicine (CBM) literature database, and the Wanfang database. The final search was performed
in July 2012. All available randomised trials that compared the effects of early progesterone cessation with
progesterone continuation during early pregnancy after IVF/ICSI were included. The main outcome measures
were live birth rate, miscarriage rate and ongoing pregnancy rate. Fixed or random-effects models were chosen
to calculate the risk ratio (RR).
Results: Six eligible studies with a total of 1,201 randomised participants were included in the final analysis. No
statistically significant differences were detected between patients who underwent early progesterone cessation
and those who received progesterone continuation for luteal phase support in terms of live birth rate (RR: 0.95,
95% CI: 0.86–1.05), miscarriage rate (RR: 1.01, 95% CI: 0.74–1.38) or ongoing pregnancy rate (RR: 0.97, 95% CI: 0.90–1.05).
These results did not change after a sensitivity analysis.
Conclusions: The currently available evidence suggests that progesterone supplementation beyond the first positive
hCG test after IVF/ICSI might generally be unnecessary, although large-scale randomised controlled trials are needed to
strengthen this conclusion.
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Approximately one million couples receive in vitro ferti-
lisation (IVF) treatment every year worldwide [1]. Luteal
phase support (LPS) has routinely been applied as part
of this treatment. The use of agonistic or antagonistic
gonadotropin-releasing hormone (GnRH) protocols in
stimulated IVF/intracytoplasmic sperm injection (ICSI)
cycles cause disruptions to the luteal phase, leading to
inadequate development of the endometrium and asyn-
chrony between endometrial receptiveness and embryo* Correspondence: qi_hongbo@yahoo.com.cn
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reproduction in any medium, provided the ortransfer. The most plausible cause of this condition is
the development of multiple follicles upon ovarian
stimulation, which results in superphysiological steroid
concentrations and consequent inhibition of luteinising
hormone (LH) secretion by the pituitary via negative
feedback at the level of the hypothalamic-pituitary
axis [2]. Despite the rapid recovery of the pituitary in
GnRH-antagonist protocols, luteolysisis also prematurely
induced after GnRH-antagonist co-treatment, resulting
in a significant reduction in luteal phase length and a
compromised reproductive outcome. For this reason,
LPS remains mandatory in GnRH antagonist protocols
used for IVF [3-5]. A large number of studies have
shown that LPS improves the clinical pregnancy rateThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remains unclear [6]. Although luteal human chorionic go-
nadotropin (hCG) supplementation has proven to be an
effective way to overcome luteal phase defects, this treat-
ment is frequently associated with an increased risk of
ovarian hyperstimulation syndrome (OHSS) [7], so the
current most widely used form of LPS is progesterone (P).
The use of P supplementation after oocyte retrieval
(OR) is almost universal, but the optimal duration of P
administration remains controversial. A recent large survey
of 84 IVF centres in 35 countries, encompassing 51,155
cycles, found that P was continued until 10–12weeks of
gestation in 67% of the cycles, whereas it was discontinued
in 22% and 12% when foetal heart pulsations were recog-
nised or when the β-hCG test was positive, respectively [8].
In the existing literature, P supplementation is variously
terminated on or near the day of a positive β-hCG test
[9-12] or extended to the day of the first ultrasound (5–7
weeks) [13], to the 8th week [14-16], or as late as the 12th
week of pregnancy [17-21]. Until recently, the available
data have been insufficient to determine the optimal dur-
ation of therapy, and prolonged P protocols have been the
rule, with most clinicians following the dictum, “better safe
than sorry” [8]. A growing body of evidence, however, has
challenged this concept and adds to the increasing concern
that P supplementation of early pregnancy after IVF/ICSI
might be unnecessary [10-14,22,23].
Four formulations of P are currently used for assisted
reproduction, including vaginal, intramuscular (i.m.),
oral and rectal preparations. Vaginal P was used for
LPS as a single agent in 64% of cycles and in another
16% of cycles in combination with either i.m. (15%) or
oral P (1%). As single agents, i.m. P was used in 13%
of cycles, oral P in another 2% and hCG in 5% [8]. Vagi-
nal P can result in similar pregnancy rates as i.m. P and
is more comfortable and tolerable to patients [24,25], but
it is more expensive. Conversely, i.m. P is often associated
with a number of side effects, including painful injections,
severe inflammatory reactions, and sterile abscesses [26].
Prolonged and repeated i.m. injections of P in oil may also
lead to delayed forms of hypersensitivity reactions, with
leukocytosis, marked eosinophilia and compromised
pulmonary activity [27,28]. Orally administered P has a
first-pass effect in which a high concentration is sent to
the portal circulation, which, in turn, results in the
production of many liver metabolites of P, some of which
may be teratogenic. Despite the available literature on
the teratogenic effects of prenatal oral P use [29,30], this
agent is still used routinely by many practitioners.
Therefore, taking into consideration the burden of LPS
treatment, the adverse reactions to P and updated
results suggesting that P supplementation during early
pregnancy after IVF/ICSI might be unnecessary, we
questioned whether the practice of early pregnancyP supplementation in IVF/ICSI patients should be
discontinued.
The aim of this study was to perform a meta-analysis of
all available randomised controlled trials (RCT) comparing
early P cessation with P continuation after assisted concep-
tion in IVF/ICSI cycles to investigate potential differences
in live birth, miscarriage and ongoing pregnancy rates. This
review was performed in accordance with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) statement principles [31].
Methods
Types of studies
The inclusion criteria for eligible studies were defined a
priori during the design phase of this systematic review.
Randomised controlled trials investigating the duration
of P supplementation for luteal phase support in IVF/
ICSI cycles were included. Trials using donor oocyte
cycles or frozen transfers were excluded. No limitations
were placed on language, date, or publication status.
Types of participants
Women undergoing IVF/ICSI who were evaluated for
the effects of P supplementation duration on pregnancy
outcomes were included.
Types of interventions
The interventions evaluated were early P cessation versus
P continuation during the first trimester in pregnant
women after IVF/ICSI.
Types of outcome measures
The primary outcome chosen for the meta-analysis was
live birth rate (LBR, i.e.,a baby born alive after 24 weeks
gestation). Secondary outcomes included ongoing preg-
nancy rate (OPR, pregnancy beyond 12 weeks of gestation,
as confirmed by foetal heart activity on an ultrasound), and
miscarriage rate (MR, the failure to achieve live birth after
a positive β-hCG test).
Literature search and data collection
We performed an exhaustive electronic search in the
following databases: MEDLINE (1946 to July 2012),
EMBASE (1974 to July 2012), the Cochrane Central
Register of Controlled Trials (CENTRAL), the Chinese
biomedicine (CBM) literature database (1978 to July
2012), and the Wanfang database (1998 to July 2012).
The search combined terms and descriptors related to
IVF, ICSI, luteal phase support, and progesterone. To fit
with the syntax used in each consulted database, the
search strategy was modified with a series of terms sug-
gestive of RCTs as set out by the Cochrane Handbook for
Systematic Review of Intervention [32](Additional file 1).
No limit was placed on language. We also carefully
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the related publications to the search. When questions
related to the design or outcomes of the trials arose, we
contacted the corresponding authors to confirm the
information we extracted from their trials or to clarify any
ambiguities.
Assessment of the risk of bias in the included studies
The risk of bias in the included studies was assessed inde-
pendently by two reviewers (Xi-Ru Liu and Hua-Qiao Mu)
according to the guidelines recommended in the Cochrane
Handbook for Systematic Review of Intervention [32].
For each study, we assessed the risk of bias related to
sequence generation, allocation, blinding of participants
and personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting and other sources of bias.
A judgment of ‘Yes’ meant a low risk of bias, a judgment of
‘No’ meant a high risk of bias, and ‘Unclear’ indicated an
unclear risk of bias. Disagreements were discussed and
resolved by consensus with a third reviewer (Qi Shi).
Data extraction and synthesis
Data extraction was performed independently by two
reviewers (Xi-Ru Liu and Hua-Qiao Mu). Discrepancies
were resolved by discussion with a third reviewer (Qi Shi).
We extracted the following information from each eligible
study: first author, year of publication, country of origin,
sample size, and a number of patient characteristics,
including the IVF protocol used, the exact dose of P,
the route of administration, the timing of initiation and
duration of luteal phase support with P, and IVF/ICSI
outcomes.
Raw data were extracted from the eligible studies for
each defined outcome and pooled using Review Manager
5.1 software. Dichotomous results from each study were
expressed as relative risk (RR) with 95% confidence
intervals (CI). These results were combined for the
meta-analysis using a fixed-effects model in the absence
of statistically significant heterogeneity or a random-
effects model in the presence of statistically significant
heterogeneity. The inter-study heterogeneity was evalu-
ated using the x2 (Cochran's Q) statistic and the I2 value.
Sensitivity analyses were performed for those studies
that answered the research question of interest but used
a quasi-randomised approach for patient allocation.
Subgroup analyses were planned a priori based on: (1) the
timing of randomisation, (2) the timing of initiation of P,
(3) the GnRH analogue used for LH surge inhibition, and
(4) the type and dose of P administration.
Results
Literature search results
A total of 1,185 trials were retrieved in the initial elec-
tronic search, 351 of which were duplicate records thatwere subsequently removed. An additional 821 were
excluded upon title/abstract screening. The 13 remaining
trials were selected for further full-text analysis. Seven of
these trials were excluded. Two were retrospective cohort
studies [10,22], and one failed to implement randomisation
[33]; one was the same study reported as an abstract at an
earlier meeting [34]; one trial did not explicitly describe the
sequence generation or allocation concealment [35]; and
two trials did not meet other inclusion criteria [18,36]. The
remaining six RCTs, totalling 1,201 participants, were
included in this meta-analysis. Detailed search procedures
are summarised in the flow diagram (Figure 1).
The methodological quality of included studies
Four of the six trials provided an adequate randomisation
model [11,13,14,23], and four an adequate mode for
allocation concealment [12-14,23], all of which made use
of sealed and opaque envelopes. One trial [17] used odd
and even patient birth years for allocation and was classified
as a quasi-randomised trial. Only one of the studies was a
dual centre study [11]; the other five were unicentric. None
of the studies blinded their personnel, participants or
outcome assessors or at least did not mention blinding.
Owing to the small number of included studies, it
was impossible to conduct a meaningful assessment
of publication bias using a funnel plot. See the risk of bias
graph (Figure 2) and risk of bias summary (Figure 3) for
an overview.
Characteristics of included studies
The six selected studies [11-14,17,23] were performed in
Spain, Belgium, Minnesota (USA), Egypt, Denmark, and
Germany, respectively, and involved 1,201 participants
who were originally studied between 1989 and 2010. In
two studies, patients with a clinical pregnancy (at 5–7
weeks of gestation) were included [13,14], and in three
studies, patients with a positive β-hCG test (on the 11-
16th day post-embryo transfer (ET)) were included
[11,17,23]. In the final study, patients were enrolled at
the beginning of an IVF cycle [12]. The type and dose of
P supplementation, the timing of administration and the
duration of P supplementation varied among the studies.
In addition, controlled ovarian hyperstimulation (COH)
protocols and the basal clinical characteristics of the
patients differed between studies. These data are presented
in Table 1.
Live birth rate
Two eligible studies presented data on live birth rates
[11,12]. In the study reported by Goudge et al. [12], the
number of patients recruited at the beginning of an IVF
cycle was converted to the number of patients with a
positive β-hCG test according to the reported biochem-
ical pregnancy rate. There were 143 events in the early P
Figure 1 Flow diagram of the systematic review and meta-analysis.
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14th day post-ET) and 150 in the P continuation group
(in which P was continued until the 6thor 7th week of
gestation). There were a total of 293 patients who gave
birth to live babies out of 369 participants. The probabil-
ity of live birth did not differ between the early P cessa-
tion group (77.3%, 143/185) and the P continuation
group (81.5%, 150/184) (P = 0.33; RR: 0.95, 95% CI:
0.86–1.05). There was no statistical heterogeneity in thisFigure 2 The risk of bias in the included studies.comparison (χ2 = 0.05, df = 1, P = 0.82; I2 = 0%)
(Figure 4).
Miscarriage rate
MR data were available from six studies, with 136 events
out of 1166 participants; after data conversion, this figure
corresponded to 69/585 in the early P cessation group
and 67/581 in the P continuation group [11-14,17,23]. No
statistical heterogeneity was observed between the studies
Figure 3 Summary of the risk of bias in the included studies.
Liu et al. Reproductive Biology and Endocrinology 2012, 10:107 Page 5 of 8
http://www.rbej.com/content/10/1/107(χ2 = 2.96, df = 5, P = 0.71; I2 = 0%). There were no
significant differences in the number of miscarriages
between patients who received early P cessation and those
who received P continuation (P = 0.96; RR: 1.01, 95% CI:





ART COH protocols Total Ini
of
Kohls, 2012 Clinical pregnancy IVF/ICSI GnRH-anta 220 OR
Kyrou, 2011 Positive hCG test IVF/ICSI GnRH-anta 200 ET
Goudge, 2010 COH IVF GnRH-a/
GnRH-anta
101 ET/
Aboulghar, 2008 Clinical pregnancy ICSI GnRH-a 257 Un
Andersen, 2002 Positive hCG test IVF/ICSI GnRH-a 303 ET
Prietl, 1992 Positive hCG test IVF CC/hMG/
GnRH-a
120 UnOngoing pregnancy rate
OPR data were available from six studies, with 1017
events among 1166 participants (503/585 in the early P
cessation group and 514/581 in the P continuation group)
[11-14,17,23]. A meta-analysis of all six trials yielded an
RR of 0.97 (P = 0.49; 95% CI: 0.90–1.05), indicating
that there was no statistically significant difference
between the early P cessation and P continuation groups
(Figure 6).
Because the OPR was heterogeneous (χ2 = 18.75, df = 5,
P = 0.002; I2 = 73%) among the included studies, a
random-effects model was used. No differences were
observed between the results obtained using a fixed-
effects model (P = 0.28; RR: 0.98; 95% CI: 0.94–1.02) and
those obtained from the random-effects model (P = 0.49;
RR: 0.97; 95% CI: 0.90–1.05), although the weight of each
study was altered. Next, according to the timing of ran-
domisation, we performed a subgroup analysis and
separately pooled four studies [11,12,17,23] in which P
was withdrawn on the day of a positive β-hCG test and
two studies [13,14] in which P was withdrawn on the day
that clinical pregnancy was confirmed (5th–7th weeks of
gestation). This stratified analysis revealed no significant
differences between the groups in which P was stopped
on the day of a positive β-hCG test (P = 0.29; RR: 0.91;
95% CI: 0.76–1.09) or on the day that clinical pregnancy
was verified (P = 0.55; RR: 1.01; 95% CI: 0.97–1.06).
Heterogeneity was detected in the subgroup of studies
that randomised patients on the day of a positive β-hCG
test (χ2 = 15.15, df = 3, P = 0.002; I2 = 80%). The study
reported by Prietl [17] might be the source of hetero-
geneity, as it used a different luteal phase support
protocol (17α-hydroxyprogesterone caproate (100mg) and
oestradiol valerate (10mg) twice a week) and exhibited a
high risk of bias based on sequence generation and patient
allocation methods. In a sensitivity analysis, we recalculated
the combined results while excluding this study. However,
the results before (P = 0.49; RR: 0.97; 95% CI: 0.90–1.05)tiation
P







vaginal P 200mg bid 110 week 5 110 week 8
vaginal P 200mg tid 100 the 16th day
post-ET
100 week 7
OR IM P50mg qd 53 the 11th day
post-ET
48 week 6
stated IM or vaginal P 125 week 6-7 132 week 9-10
vaginal P 200mg tid 150 the 14th day
post-ET
153 week 7
stated PC500mg/EV10mg tiw 65 the 12th day
post-ET
55 week 12
Figure 4 Live birth rate of women who underwent early P cessation versus P continuation after IVF/ICSI.
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0.96–1.06) were not significantly different.
Discussion
Although there is no firm evidence to support the continu-
ation of LPS until the 10th to 12th week of gestation, this
practice is used in the majority of IVF cycles worldwide [8].
This review compared the effects of early cessation with
continuation of P supplementation for luteal phase support
in pregnant women after IVF/ICSI, focusing on the live
birth, ongoing pregnancy and miscarriage rates. The
pooled results showed no significant differences in LBR
between groups in which P supplementation was stopped
on the day of a positive β-hCG test or for whom P supple-
mentation was continued up to the 6th to 7th week of ges-
tation. Similarly, the miscarriage and ongoing pregnancy
rates were not affected by the duration of P administration.
Because there was statistical heterogeneity in the studies
analysed for OPR, we performed a subgroup analysis and a
sensitivity analysis. The results of the subgroup analysis
were in accordance with the above results. The findings
were also stable after the sensitivity analysis, which
excluded one study [17] in which odd or even patient birth
years were used for patient allocation. Based on this
analysis, we find no convincing evidence to support the
routine use of P supplementation during early pregnancy
in women undergoing IVF/ICSI. It is possible that the
establishment of a pregnancy and rescue of the corpus
luteum via trophoblastic hCG may make up for theFigure 5 Miscarriage rate of women who underwent early P cessationpossible luteal phase defect caused by the stimulated
IVF cycles.
Most of the studies included in this review described
their methods of sequence generation and allocation
concealing. However, none of the studies mentioned
blinding. Keeping trial participants, personnel, or assessors
blinded to the assigned intervention might reduce the
influence of subjective psychological factors on pregnancy
outcomes, an important aspect of RCTs. However, owing
to the nature of current LPS studies, absolute double
blinding is often not practical, as it is not possible to blind
the participants. None of the studies explicitly mentioned
blinding of personnel or outcome assessors. Nevertheless,
it is unlikely that pregnancy outcomes such as live birth,
miscarriage or ongoing pregnancy can be affected by
detection bias. In future studies, proper blinding protocols
using a double-dummy design should be implemented,
and a placebo control group should be established.
Due to the small number of studies that met the inclu-
sion criteria and the different clinical characteristics of
the participants, it was impossible to conduct meaningful
subgroup analyses based on the initiation of P supplemen-
tation, the GnRH analogue used for luteinising hormone
surge inhibition, or the type or dose of P administration.
These analyses might become practical upon the accumu-
lation of further studies. We were only able to analyse
studies according to the different timing of randomisa-
tion, a potential source of clinical heterogeneity; here, we
pooled the data from studies with similar enrolmentversus P continuation after IVF/ICSI.
Figure 6 Ongoing pregnancy rate of women who underwent early P cessation versus P continuation after IVF/ICSI.
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tioned parameters do vary among the included studies,
and we do not know whether these clinical variables
might be associated with the effects of P supplementation
on pregnancy outcomes. For example, P supplementation
was initiated at different time-points in these studies.
These were no significant differences between initiation
on the day of OR or on the day of ET with regard to clinical
pregnancy, ongoing pregnancy, or live birth rates, according
to recent reports [36,37]. One study suggested that delaying
the LPS until six days after OR can decrease the pregnancy
rate [38]. Because P administration was initiated on the day
of OR or ET in most of the eligible studies in our analysis,
it is unlikely that these discrepancies affected our results. In
a word, our results require confirmation in further studies
in which the baseline of different groups is comparable to
the greatest possible extent.
Two important limitations of our meta-analysis should
be noted: (1) only six studies were included in this
review, and the number of patients analysed is far below
the sample size required to exclude a clinically import-
ant difference. A non-inferiority trial showing a differ-
ence of −4% or larger from a live birth rate of 80%
would require a sample size of 3,140 women with a posi-
tive pregnancy test after IVF [39]. (2) The external valid-
ity of the study may be limited because existing studies
excluded those patients with early bleeding, advanced
age or polycystic ovary syndrome as well as those
patients with an inadequate hCG rise or endometriosis,
whose luteal phase may behave differently. Future trials
should recruit such patients to better stratify the outcomes
for these patient groups.
Conclusions
In conclusion, based on the currently available evidence,
progesterone supplementation might be unnecessary
beyond the first positive β-hCG test after IVF/ICSI.However, considering the large number of IVF cycles
performed globally and the side effects and costs of
progesterone treatment, additional well-designed RCTs
are urgently needed to investigate the optimal duration
of progesterone administration during early pregnancy
in women undergoing IVF/ICSI.Additional file
Additional file 1: Search strategy in MEDLINE, EMBASE, and
CENTRAL databases.
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